Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
- Shionogi Kicks Off COVID-19 Booster Trial in Japan
December 6, 2021
- Mitsubishi Tanabe, Janssen to Copromote Dyskinesia Med in Japan
December 6, 2021
- Bayer Yakuhin President Julio Triana to Double as Bayer Holding Japan Chief
December 6, 2021
- MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
- Sawai to Acquire Kobayashi Kako’s Manufacturing Sites, Staffers
December 3, 2021
- Astellas, Dyno Therapeutics to Collaborate in R&D of Next-Generation AAV Vectors
December 3, 2021
- Shionogi Earns Taiwan Nod for Constipation Treatment Symproic
December 3, 2021
- Enhertu Enters Global PIII for Neoadjuvant Therapy for Breast Cancer: Daiichi Sankyo
December 2, 2021
- Moderna Names Ex-Ferring Japan CEO Rami Suzuki as Japan Chief
December 2, 2021
- Nippon Shinyaku Launches Paid Access Program for Viltepso
December 1, 2021
- Kaken to Acquire Takeda Spinout to Expand Development Pipeline
December 1, 2021
- Taiho Exercises Option to Grab Arcus’ Anti-TIGIT Antibodies
December 1, 2021
- Takeda to Succeed Fabry Disease Med from Sumitomo Dainippon
December 1, 2021
- Blaze at Hitachi Logistic Center Could Add to Drug Supply Woes
December 1, 2021
- BMS Files Psoriasis Drug Deucravacitinib in Japan
December 1, 2021
- Astellas’ ADC Padcev Now Available in Japan
December 1, 2021
- Takeda Rolls Out Crohn’s Disease Cell Therapy Alofisel in Japan
December 1, 2021
- Lenvima/Keytruda Bags EU Approval for RCC, Endometrial Carcinoma
November 30, 2021
- Japan Makers Racing to Study Vaccines for Omicron Variant
November 30, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…